Lakefront Biotherapeutics (LKFT) Inventory Average (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has 9 years of Inventory Average data on file, last reported at $23.4 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $23.4 million, down 50.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.4 million (down 50.75% YoY), and the FY2025 annual result was $40.4 million, down 39.77% from the prior year.
• Inventory Average eased to $23.4 million in Q1 2026 per LKFT's latest filing, from $26.5 million in the prior quarter.
• Over five years, Inventory Average peaked at $83.6 million in Q1 2024 and troughed at $22.1 million in Q1 2022.
• A 5-year average of $46.3 million and a median of $43.5 million in 2025 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2023 and 2025: Inventory Average jumped 148.0% in 2023, then tumbled 58.16% in 2025.
• A 5-year view of Inventory Average shows it stood at $22.1 million in 2022, then jumped by 217.18% to $70.1 million in 2023, then declined by 9.58% to $63.4 million in 2024, then plunged by 58.16% to $26.5 million in 2025, then declined by 11.53% to $23.4 million in 2026.
• Business Quant data shows LKFT's Inventory Average at $23.4 million in Q1 2026, $26.5 million in Q4 2025, and $32.5 million in Q3 2025.